Hepatitis E

01Pathophysiology

Hepatitis E virus is a small, non-enveloped, single-stranded positive-sense RNA virus belonging to the family Hepeviridae. It is transmitted primarily through the fecal-oral route, most commonly via contaminated drinking water in endemic regions. This is the hallmark transmission pathway tested in exam vignettes, and it distinguishes HEV from bloodborne hepatitis viruses (B and C).

HEV has four major genotypes relevant to clinical practice. Genotypes 1 and 2 are restricted to humans and are responsible for the large waterborne epidemics seen in developing countries. Genotypes 3 and 4 are zoonotic, circulating in animal reservoirs such as pigs, deer, and wild boar. In developed countries, sporadic cases of HEV are typically caused by genotype 3, acquired through consumption of undercooked pork or game meat. This zoonotic route is increasingly tested as an emerging concept.

Once ingested, the virus replicates in the hepatocytes, triggering a host immune-mediated cytotoxic T-cell response that causes hepatocellular injury. This is similar to Hepatitis A in that the liver damage is not directly cytopathic but rather immunologically driven. The resulting hepatocyte necrosis produces elevated serum aminotransferases (AST and ALT), conjugated hyperbilirubinemia, and the clinical picture of acute viral hepatitis.

The single most important pathophysiologic concept for exam purposes is the association between HEV and fulminant hepatic failure in pregnant women, particularly during the third trimester. The mortality rate in this population can reach 20 to 25%, a figure that is dramatically higher than the less than 1% mortality in the general population. The exact mechanism is not fully understood, but it is thought to involve hormonal and immunological changes during pregnancy (including a shift toward Th2 immune dominance and altered viral replication kinetics in the setting of elevated steroid hormones) that predispose to overwhelming hepatic necrosis. When you see a vignette describing a pregnant woman returning from South Asia with acute jaundice and liver failure, Hepatitis E should be at the top of your differential.

In immunocompromised patients, particularly solid organ transplant recipients on chronic immunosuppression, HEV genotype 3 can establish chronic infection. The virus evades clearance due to the suppressed T-cell response, leading to persistent viremia, chronic hepatitis, and progressive fibrosis that can advance to cirrhosis. This is a newer but increasingly testable concept: HEV is one of the few hepatitis viruses that can cause chronic disease specifically in the immunosuppressed population, not in the general population.

02Classification and Clinical Manifestation

Extrahepatic manifestations of HEV are less commonly tested but worth noting. Genotype 3 infections have been associated with neurological complications including Guillain-Barre syndrome, neuralgic amyotrophy (Parsonage-Turner syndrome), and Bell palsy. Renal complications such as membranoproliferative glomerulonephritis and cryoglobulinemia have also been described. These extrahepatic features are more common in chronic HEV infections in immunosuppressed patients.

03Diagnostic Workup

The diagnostic approach to Hepatitis E follows a logical sequence. In a patient presenting with acute hepatitis and a relevant epidemiological history (travel, water exposure, pregnancy), the first step is to obtain liver function tests, which will show markedly elevated transaminases with a hepatocellular pattern (ALT > AST). You then need to rule out the more common causes of acute viral hepatitis by checking serologies for Hepatitis A (anti-HAV IgM), Hepatitis B (HBsAg, anti-HBc IgM), and Hepatitis C (anti-HCV, HCV RNA).

Once A, B, and C have been excluded, the best initial test for Hepatitis E is the anti-HEV IgM antibody. This becomes positive early in the course of illness, typically around the time of symptom onset, and persists for approximately 3 to 6 months. A positive result in the right clinical context is often sufficient to make the diagnosis.

However, serology has important limitations. Anti-HEV assays are not standardized across all laboratories, and sensitivity can vary. In immunocompromised patients, antibody production may be blunted, leading to false-negative serology. For this reason, the most accurate (confirmatory) test is HEV RNA detection by reverse transcription polymerase chain reaction (RT-PCR) in serum or stool. This is the gold standard and is essential for diagnosing chronic HEV infection in transplant recipients, where serologic tests are unreliable.

For exam purposes, remember: when you see a vignette with negative Hepatitis A, B, and C serologies in a patient with acute hepatitis and a travel or exposure history, the next step is anti-HEV IgM. If the question asks for the "most accurate" or "definitive" test, the answer is HEV RNA PCR.

In cases of suspected fulminant hepatic failure, always check PT/INR and albumin to assess synthetic liver function. An elevated INR is a red flag for impending liver failure and may prompt consideration of liver transplantation.

04Management and Treatment

Acute Hepatitis E in immunocompetent patients is a self-limited disease. No antiviral therapy is indicated. Management is entirely supportive: oral hydration, rest, dietary support, and avoidance of hepatotoxic substances. The illness typically resolves within 4 to 6 weeks without sequelae. This is analogous to the management of Hepatitis A, and exam questions may test whether you inappropriately choose antiviral therapy for a straightforward acute case.

In pregnant women, the management remains supportive because there is no proven safe antiviral therapy during pregnancy. Ribavirin is a known teratogen (FDA pregnancy category X) and is absolutely contraindicated. The critical management step is close monitoring for signs of fulminant hepatic failure: worsening coagulopathy, encephalopathy, and rising bilirubin with falling transaminases (a sign of hepatocyte collapse). If fulminant failure develops, the patient should be urgently transferred to a facility capable of performing liver transplantation. Early delivery may be considered to improve maternal outcomes, though evidence is limited.

Chronic Hepatitis E is managed in a stepwise fashion. The first step is to reduce immunosuppression, which alone can achieve viral clearance in about 30% of patients. If viremia persists after immunosuppression reduction, ribavirin is initiated as the primary antiviral agent. The standard regimen is 600 to 800 mg per day orally, continued for a minimum of 3 months, with many experts recommending 6 months of therapy. Treatment success is defined as a sustained virologic response: undetectable HEV RNA at 6 months after completing therapy. For the rare patient who fails ribavirin, pegylated interferon-alpha may be considered, but this carries a high risk of graft rejection in transplant recipients and is used only in carefully selected cases.

There is currently no widely approved vaccine for Hepatitis E. A recombinant vaccine (Hecolin, HEV 239) has been licensed in China but is not available globally. Prevention in endemic areas relies on clean water supply, sanitation, and hygiene measures. In developed countries, avoidance of undercooked pork and game meat reduces the risk of zoonotic transmission.

05Differential Diagnosis and Distractors

The most commonly tested distractor is Hepatitis A, because both share fecal-oral transmission, travel-associated acute hepatitis, and a self-limited course. The key discriminator is twofold: first, the serologic markers are different (anti-HAV IgM vs. anti-HEV IgM); second, and more importantly for the exam, Hepatitis A does not cause high mortality in pregnant women, while Hepatitis E does. If the vignette features a pregnant woman with acute hepatitis and liver failure after travel to an endemic region, the answer is Hepatitis E, not A.

The other important distractor is HELLP syndrome or acute fatty liver of pregnancy when the vignette describes liver disease in a pregnant patient. The key discriminator is the presence of viral markers (positive anti-HEV IgM) and the absence of the hematologic findings characteristic of HELLP (thrombocytopenia, hemolysis) or the metabolic derangements of AFLP (profound hypoglycemia, hyperuricemia).

06Traps and High-Yield Pearls

The most common way students lose points on Hepatitis E questions is by confusing it with Hepatitis A. Both are fecal-oral, both are self-limited, and both are associated with travel. However, the test-writer uses pregnancy as the distinguishing clinical scenario. When a vignette presents a pregnant woman (especially in the third trimester) with acute hepatitis after travel to South or Southeast Asia, the answer is Hepatitis E. The mortality rate of 20 to 25% in pregnant women is one of the most tested numerical associations in all of hepatology, and it is unique to HEV.

A second trap involves chronic Hepatitis E in immunocompromised patients. Many students incorrectly assume that HEV is always acute and self-limited. However, in solid organ transplant recipients, HEV genotype 3 can persist and progress to cirrhosis. If a post-transplant patient presents with chronically elevated liver enzymes and no identifiable cause, HEV RNA testing should be ordered. The stepwise management (reduce immunosuppression first, then ribavirin) is a testable treatment algorithm.

A third trap is the inappropriate use of ribavirin in pregnancy. If a vignette asks for treatment of HEV in a pregnant woman, supportive care is the only correct answer. Ribavirin is teratogenic, and selecting it is a classic wrong-answer choice designed to test whether you know the drug's contraindications.

The core competency being tested across Hepatitis E questions is pattern recognition: identifying the classic epidemiological setup (waterborne transmission, endemic travel, pregnancy) and knowing the serologic and molecular diagnostic sequence (anti-HEV IgM as best initial test, HEV RNA PCR as confirmatory). Secondary competencies include understanding the unique risk to pregnant patients and the management of chronic HEV in transplant recipients.